Texas

Directed the Texas Health and Human Services Commission, in collaboration with Baylor College of Medicine and in partnership with a veterans hospital or military medical center, to conduct a study on the use of alternative therapies including MDMA, psilocybin, and ketamine for treating PTSD in veterans. Required a clinical trial on psilocybin for treatment-resistant PTSD and a review of the published literature on all three substances. Passed both chambers and was filed without the governor's signature, taking effect immediately on June 18, 2021. The state-funded research authorized under HB 1802 is associated with the STARLIGHT trial at Baylor College of Medicine, an open-label study of psilocybin-assisted therapy for veterans with PTSD (ClinicalTrials.gov NCT06888128).

Would have established a state-backed study under the Texas Health and Human Services Commission on the use of psychedelic therapies — specifically MDMA, psilocybin, and ketamine — for treating PTSD, depression, and other mental health disorders. The bill required a final report to the Legislature by December 1, 2026 with recommendations to ensure patient access following any future FDA approval. Passed the Texas House on May 8, 2025 (115–31) and was sent to the Senate, where it was referred to the Senate Health & Human Services Committee on May 19, 2025 and received no further action before the 89th Regular Session adjourned sine die on June 2, 2025. Companion bill: SB 3005 (Sen. Cesar Blanco, D), which also did not advance.

Would have directed the Texas Department of State Health Services commissioner to reschedule any controlled substance under Texas state law 'as soon as practicable' after the U.S. Food and Drug Administration approves the substance for medical use or removes it from the federal controlled substances schedule. The bill was designed to work in tandem with HB 4014 (Bucy) to minimize delay in Texas patient access to FDA-approved psychedelic-assisted therapies such as psilocybin and MDMA. Passed the Texas House unanimously (146–0 on third reading) and was sent to the Senate, referred to Senate Health & Human Services on May 13, 2025, and received no further action before the 89th Regular Session adjourned sine die on June 2, 2025. Companion bill: SB 2997.

Establishes a public-private consortium — comprising an institution of higher education, a hospital, and a drug developer — administered by the Texas Health and Human Services Commission, to conduct FDA drug-development clinical trials of ibogaine for opioid use disorder, co-occurring substance use disorder, and other neurological and mental health conditions. Backed by $50 million in state matching funds, with Texas retaining a commercial interest in resulting intellectual property (a quarter of any state IP revenue directed to veterans programs). Described by supporters as the largest state-funded psychedelic research initiative to date. Enacted via the SB 2308 vehicle; the companion House measure was HB 3717 (Rep. Cody Harris), which was laid on the table subject to call. This is the bill referenced on the imicrodosing.net San Antonio page.